Literature DB >> 1603086

Characterization of estrogen receptor variant mRNAs from human breast cancers.

H Dotzlaw1, M Alkhalaf, L C Murphy.   

Abstract

The cDNAs for variant estrogen receptor (ER) mRNAs previously identified in human breast cancer biopsy samples have been cloned and characterized. Some of these cDNAs are unique to a tumor sample (e.g. clones 24 and 5), while others are present in multiple breast tumor samples (e.g. clone 4). The 5' ends of the variant cDNAs are essentially identical to sequences present in exons 1, 2, and 3 of the normal ER mRNA. However, at points which mark either the exon 2/intron or exon 3/intron boundaries, the variant cDNA sequences diverge and are unrelated to the normal ER mRNA. The unique sequences of clones 24 and 5 are unknown, and the unique sequence of clone 4 is related to the long interspersed repetitive LINE-1 sequences. The variant mRNAs contain open reading frames which could encode proteins containing known functional domains of the normal ER but missing others. In particular, the hormone binding domain of the normal ER is always missing. Furthermore, some of the variant transcripts may encode other unique proteins. In transient expression assays the proteins encoded by the variant ER mRNAs are unable to activate transcription of an estrogen-responsive reporter gene; neither are they able to modulate the ability of normal ER proteins to activate transcription.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1603086     DOI: 10.1210/mend.6.5.1603086

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  22 in total

1.  Expression of estrogen receptor variant messenger RNAs and determination of estrogen receptor status in human breast cancer.

Authors:  A Huang; E R Leygue; L Snell; L C Murphy; P H Watson
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 2.  Regulatory factor X4 variant 3: a transcription factor involved in brain development and disease.

Authors:  Donghui Zhang; Darryl C Zeldin; Perry J Blackshear
Journal:  J Neurosci Res       Date:  2007-12       Impact factor: 4.164

3.  Triple primer polymerase chain reaction. A new way to quantify truncated mRNA expression.

Authors:  E Leygue; L Murphy; F Kuttenn; P Watson
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

Review 4.  Cell-specific mechanisms of estrogen receptor in the pituitary gland.

Authors:  F Demay; S Geffroy; C Tiffoche; M de Monti; M L Thieulant
Journal:  Cell Biol Toxicol       Date:  1996-12       Impact factor: 6.691

5.  Genetic variants of EGFR (142285G>A) and ESR1 (2014G>A) gene polymorphisms and risk of breast cancer.

Authors:  Ranbir Chander Sobti; Marjan Askari; Mohsen Nikbakht; Neha Singh; Suresh C Sharma; Abayneh Munshea Abitew
Journal:  Mol Cell Biochem       Date:  2012-07-19       Impact factor: 3.396

6.  Tamoxifen aziridine labeling of the estrogen receptor-potential utility in detecting biologically aggressive breast tumors.

Authors:  S Trivedi; M Piccart; C Muquardt; N Gilot; S Hadiy; D Patel; G Leclercq
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

7.  Investigation of the origin of variant, truncated estrogen receptor-like mRNAs identified in some human breast cancer biopsy samples.

Authors:  L C Murphy; H Dotzlaw; J Hamerton; J Schwarz
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

8.  Estrogen regulates the expression of several different estrogen receptor mRNA isoforms in rat pituitary.

Authors:  K E Friend; L W Ang; M A Shupnik
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

Review 9.  Mechanisms of hormone resistance in breast cancer.

Authors:  K B Horwitz
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 10.  William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy.

Authors:  D M Wolf; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.